How Will COVID-19 Change Telehealth and Alternative Payment Models?

Lockdowns instituted due to the COVID-19 pandemic could have brought about exacerbated immune responses in people living with HIV.

The editors in chief of The American Journal of Managed Care® discuss the key managed care research and news from 2024 and look forward to the journal’s upcoming 30th anniversary.

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.

Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic HER2-negative (HER–) gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1.

Sara Grethlien, MD, MBA, FACP, Swedish Cancer Institute, looks ahead to the future of oncology care and important value-based care considerations.